Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) EBT Margin (2016 - 2025)

Historic EBT Margin for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to 37.65%.

  • Cytosorbents' EBT Margin fell 55100.0% to 37.65% in Q3 2025 from the same period last year, while for Sep 2025 it was 50.13%, marking a year-over-year increase of 79300.0%. This contributed to the annual value of 62.96% for FY2024, which is 337500.0% up from last year.
  • As of Q3 2025, Cytosorbents' EBT Margin stood at 37.65%, which was down 55100.0% from 44.0% recorded in Q2 2025.
  • In the past 5 years, Cytosorbents' EBT Margin ranged from a high of 16.94% in Q1 2025 and a low of 150.42% during Q3 2022
  • For the 5-year period, Cytosorbents' EBT Margin averaged around 69.33%, with its median value being 65.64% (2021).
  • Data for Cytosorbents' EBT Margin shows a peak YoY increase of 733500bps (in 2022) and a maximum YoY decrease of -891600bps (in 2022) over the last 5 years.
  • Cytosorbents' EBT Margin (Quarter) stood at 93.14% in 2021, then skyrocketed by 79bps to 19.79% in 2022, then plummeted by -331bps to 85.23% in 2023, then decreased by -19bps to 101.17% in 2024, then soared by 63bps to 37.65% in 2025.
  • Its last three reported values are 37.65% in Q3 2025, 44.0% for Q2 2025, and 16.94% during Q1 2025.